Beam Therapeutics
Price & Volume
Stats
See moreOpen | $32.50 |
Previous Close | $32.80 |
Day Range | $32.20-$33.61 |
52W Range | $15.60-$36.44 |
Market Cap | $3.3B |
Shares Short | 26M |
Financials
See moreRevenue (12 Mos) | $164M |
Revenue Growth (YoY) | 324.9% |
Gross Profit (12 Mos) | -$240.9M |
Diluted EPS | -$0.49 |
News
See moreYahoo Finance • 4 days ago
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
Yahoo Finance • 11 days ago
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
Yahoo Finance • 17 days ago
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
Yahoo Finance • 18 days ago
Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates
About
CEO | Mr. John M. Evans M.B.A. |
Address | 238 Main Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 522 |